Anti-Human CCL-19-Anti-Human CCL-19代理/參數(shù)/廠家-一抗-艾美捷科技有限公司

PRODUCT CENTER

一抗

產(chǎn)品中心

當(dāng)前位置：首頁 > 產(chǎn)品中心 > 免疫學(xué)產(chǎn)品 > 一抗

購買方式: 90%產(chǎn)品中國有現(xiàn)貨庫存。銀行轉(zhuǎn)賬、電匯、支票、現(xiàn)金，在線支付寶及網(wǎng)銀支付，或直接與我們電話聯(lián)系400-6800-868

背景資料: CCL19, also known as MIP3β and ELC (EBI1Ligand Chemokine), is a 77 amino acid (aa) β chemokine that is distantly related to other β chemokines (20-30% aa sequence identity). The gene for MIP3β has been mapped to chromosome 9p13 rather than chromosome 17 where the genes for many human β chemokines are clustered. MIP3β is constitutively expressed in various lymphoid tissues (including thymus, lymph nodes, appendix and spleen). The expression of MIP3β is downregulated by the antiinflammatory cytokine IL10. Recombinant MIP3β is chemotactic for cultured human lymphocytes. MIP3β is a ligand for CCR7 (previously referred to as the EpsteinBarr virus-induced gene 1 (EBI1) orphan receptor), a chemokine receptor that is expressed in various lymphoid tissues and activated B and T lymphocytes. CCR7 is strongly upregulated in B cells infected with EpsteinBarr virus and T cells infected with herpesvirus 6 or 7.

保存建議: 該Anti-Human CCL-19的詳細(xì)信息查看ReliaTech提供的產(chǎn)品說明書。溶解建議：Centrifuge vial prior to opening. Reconstitute the antibody with 500 μl sterile PBS and the final concentration is 200 μg/ml.

其他: ReliaTech全稱為受體配體技術(shù)有限公司 (Receptor Ligand Technologies GmbH)，1999年成立，總部位于德國不倫瑞克，是一家后基因組生物技術(shù)公司。ReliaTech主要專注于受體和配體的發(fā)現(xiàn)與研究。此外，ReliaTech也開發(fā)應(yīng)用于血管與淋巴管生成研究的相關(guān)高品質(zhì)試劑。目前ReliaTech提供近2800款產(chǎn)品，產(chǎn)品線主要包括重組蛋白(細(xì)胞因子、生長因子、可溶性受體)、抗體、ELISA試劑盒等。